Humana Stock Price and Value Analysis

Humana (NYSE:HUM) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: HUM (NYSE)
  • Current price: $390.00
  • Sector: Unknown
  • Industry: Unknown
  • Dividend yield: 0.93%

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Humana to reach your target.

Target type

HUM Free Cash Flow Trend

Free Cash Flow trendline for HUM
Free Cash Flow trendline for Humana
CSV

Based on historical returns, we believe that Humana can grow its free cash at a rate of about 9%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This company is very stable.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company has a low dividend yield.

Inside the HUM Numbers

HUM Price
(Humana stock price per share)
$390.00
[?] HUM Fair Price
(based on intrinsic value)
$210.74
[?] HUM Safety Price (based on a variable margin of safety) $168.59
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 10% lower than other Unknown stocks
[?] PE Ratio versus Industry 37% higher than other Unknown stocks
[?] Cash Yield 0.76%
[?] Free Cash Flow Jitter 63%
[?] Dividend Yield 0.93% (tax impact)
Shares Shorted 2,779,968

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,779,968 shares shorted. With 119,858,239 shares available for purchase and an average trading volume over the past 10 trading days of 2,235,510, it would take at least 1.2 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 49071 985
2008 49071 732
2009 49071 1,193
2010 49071 2,015
2011 49071 1,828
2012 49071 1,638
2013 49071 1,395
2014 49071 1,229
2015 49071 418
2016 49071 1,450
2017 49071 3,542
2018 49071 1,630
2019 49071 4,700
2020 49071 4,966
2021 49071 1,426
2022 49071 3,629
2023 49071 2,944
2024 49071 1,962
2025 49071 0.2

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $47,875 million against net income of $31,357 million, or 1.53 times.

In 2025, operating cash flow was 0.78 times net income, compared with 1.44 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $546 million, 59.3% of operating cash flow of $921 million, which leaves an estimated $375 million after capex. Across the 19 years with reported capex, it averaged 23.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 0.78, below 0.80, so under 80% of reported net income arrived as operating cash and at least 0.25 under the 1.44 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 834 1,224 239 1.47
2008 647 982 262 1.52
2009 1,040 1,422 185 1.37
2010 1,099 2,242 222 2.04
2011 1,419 2,079 346 1.47
2012 1,222 1,923 410 1.57
2013 1,231 1,716 441 1.39
2014 1,147 1,618 528 1.41
2015 1,276 868 523 0.68
2016 614 1,936 527 3.15
2017 2,448 4,051 524 1.65
2018 1,683 2,173 612 1.29
2019 2,707 5,284 736 1.95
2020 3,367 5,639 964 1.67
2021 2,933 2,262 1,342 0.77
2022 2,806 4,587 1,137 1.63
2023 2,489 3,981 1,004 1.60
2024 1,207 2,966 575 2.46
2025 1,188 921 546 0.78

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $26,250 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $3,314 million, 12.6% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $12,165 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $581 million, 290500.0% of estimated free cash flow of $0.2 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 1,450 177 104 281 19.4%
2017 3,542 220 3,365 3,585 101.2%
2018 1,630 265 1,090 1,355 83.1%
2019 4,700 291 1,070 1,361 29.0%
2020 4,966 323 1,820 2,143 43.1%
2021 1,426 354 79 433 30.4%
2022 3,629 392 2,096 2,488 68.6%
2023 2,944 431 1,573 2,004 68.1%
2024 1,962 431 817 1,248 63.6%
2025 0.2 430 151 581 290500.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $25,290 million in 2007 and $129,664 million in 2025, a compound annual growth rate of 9.5% over 18 years.

Revenue rose 10.1% from 2024 to 2025.

Our estimated free cash flow was $0.2 million in 2025, 0.0% of revenue. In 2007 the estimated margin was 3.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 25,290 985 3.9%
2008 28,946 732 2.5%
2009 30,743 1,193 3.9%
2010 33,596 2,015 6.0%
2011 36,832 1,828 5.0%
2012 39,126 1,638 4.2%
2013 41,313 1,395 3.4%
2014 48,500 1,229 2.5%
2015 54,289 418 0.8%
2016 54,379 1,450 2.7%
2017 53,767 3,542 6.6%
2018 56,912 1,630 2.9%
2019 64,888 4,700 7.2%
2020 77,155 4,966 6.4%
2021 83,064 1,426 1.7%
2022 92,870 3,629 3.9%
2023 106,374 2,944 2.8%
2024 117,761 1,962 1.7%
2025 129,664 0.2 0.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $4,200 million against total liabilities of $31,172 million, or 13.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 63.7% of total assets in 2025, compared with 65.8% in 2008, a decrease of 2.1 percentage points.

Stockholders equity was $17,737 million in 2025, compared with $4,457 million in 2008, a rise of 298.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 0.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 13,042 1,970 8,585 4,457
2009 14,153 1,613 8,377 5,776
2010 16,103 1,673 9,179 6,924
2011 17,708 1,377 9,645 8,063
2012 19,979 1,306 11,132 8,847
2013 20,735 1,138 11,419 9,316
2014 23,527 1,935 13,881 9,646
2015 24,678 2,571 14,332 10,346
2016 25,396 3,877 14,711 10,685
2017 27,178 4,042 17,336 9,842
2018 25,413 2,343 15,252 10,161
2019 29,074 4,054 17,037 12,037
2020 34,969 4,673 21,241 13,728
2021 44,358 3,394 28,255 16,103
2022 43,055 5,061 27,685 15,370
2023 47,065 4,694 30,747 16,318
2024 46,479 2,221 30,034 16,445
2025 48,909 4,200 31,172 17,737

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $390.00, our model's value equals that price if free cash flow grows an average of 27.6 percent a year over the 10 projection years. Our model assumes 9.2 percent a year for this stock, so the price implies growth of 27.6 percent, which is above the 9.2 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 27.6 percent a year, free cash flow would grow about 11.4 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $346 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $312.00 22.1%
Current price $390.00 27.6%
20 percent above the current price $468.00 31.5%
Our model (stored fair price) $210.74 9.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for Humana under its current filer shows positive free cash flow.

At $390.00, Humana trades above our fair value estimate of $210.74.

Comparing the first and last three years of data, average free cash flow rose sharply: $970 million at the start and $1,635 million most recently.

Free cash flow is volatile from year to year, with a variability measure of 63%.

Humana yields 0.93% in dividends.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 49071.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: HUM annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HUM

Does Humana have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HUM

This example shows how we apply the Trendshare checklist to HUM: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 390.00
    • Market cap: $47B
    • EPS: 10.25
  2. Step 2 — Valuation checks

    • P/E: 38.049
    • FCF yield: 0.7%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.